CNTX CONTEXT THERAPEUTICS INC

EQS-News: Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

EQS-News: Context Therapeutics
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

06.12.2022 / 12:40 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Investors USA

Proactive Investors USA


News Source: News Direct

06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Context Therapeutics
United States
ISIN: US21077P1084
EQS News ID: 1506291

 
End of News EQS News Service

1506291  06.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1506291&application_name=news&site_id=research_pool
EN
06/12/2022

Underlying

CNTXCONTEXT THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEXT THERAPEUTICS INC

 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designa...

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administra...

10h / 52m 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics Reports Full Year 2025 Operating and Financial Re...

Context Therapeutics Reports Full Year 2025 Operating and Financial Results Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, to...

March 23, 2026 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics to Participate in Upcoming Investor Conferences PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences. Upcoming Investor Conferences Guggenheim Emerging Outlook: Biotech Summit 2026, February 11-12, 2026, New York, NYFireside Chat: Wednesday, February 11th at 8:30 AM ET1x1 Meetings on February 11th TD Cowen 46th Annual H...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context. The stock option awards were granted outside of the Cont...

January 16, 2026 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC...

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company’s CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD. CT-95 and CT-202 Highlights and Near-Term Milestones CT-95: Mesothel...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch